What's the one thing that teams consistently underestimate when scaling viral vectors?

I think a lot of people for a long time have kind of preached analytics, that you don't have sufficient analytics for that.

I think the other piece, so I will say, I think a large portion of folks will say that.

I would agree with that.

I think the other thing that people forget is we're still kind of at the beginning, right? You want to be, you think, well, gene therapy has been around for 30 years.

Why isn't it where monoclonals are at? Why don't I have, you know, I think a lot of senior staff are always, executives are like, why isn't this $1,000 a vial, right? Or why isn't it at least $10,000 a vial? And I think we're just not there yet because people keep putting new modalities on top of, you know, early on we saw retrovirus being used routinely and liposomes for delivery.

And now we've kind of moved into lentivirus, MBA, you know, adenovirus for a long time.

assumptions